Advanced search
Publication Cover
Clinical and Experimental Gastroenterology Volume 13, 2020 - Issue
Submit an article Journal homepage
137
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis

Katsuaki Ogushi1 Gastroenterological Center, Yokohama City University Medical Center, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0001-7968-8933
ORCID Icon,
Makoto Chuma1 Gastroenterological Center, Yokohama City University Medical Center, Yokohama, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0963-9172
ORCID Icon,
Haruki Uojima2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
,
Hisashi Hidaka2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, JapanORCID Iconhttps://orcid.org/0000-0002-4151-5663
ORCID Icon,
Kazushi Numata1 Gastroenterological Center, Yokohama City University Medical Center, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0003-4671-4431
ORCID Icon,
Satoshi Kobayashi3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan
,
Shunji Hirose4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
,
Nobuhiro Hattori5 Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
,
Tomoaki Fujikawa6 Department of Gastroenterology, Shonan Fujisawa General Hospital, Fujisawa, Japan
,
Takahide Nakazawa2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
,
Naohisa Wada2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
,
Shuitirou Iwasaki2 Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
,
Taito Fukushima3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan
,
Yusuke Sano3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0001-7753-8712
ORCID Icon,
Makoto Ueno3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0003-4480-0029
ORCID Icon,
Kuniyuki Kawano3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan
,
Kota Tsuruya4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, JapanORCID Iconhttps://orcid.org/0000-0002-9884-8039
ORCID Icon,
Masako Shomura4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
,
Tsunamasa Watanabe5 Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
,
Kotaro Matsunaga5 Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
,
Yosuke Kunishi7 Department of Gastroenterology, Kanagawa Prefectural Ashigarakami Hospital, Kanagawa, Japan
,
Yusuke Saigusa8 Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, JapanORCID Iconhttps://orcid.org/0000-0003-4785-7653
ORCID Icon,
Kuniyasu Irie9 Department of Gastroenterology, Yokohama City University Hospital, Yokohama, Japan
,
Shogo Iwabuchi6 Department of Gastroenterology, Shonan Fujisawa General Hospital, Fujisawa, Japan
,
Makoto Kako10 Department of Gastroenterology, Shonan Kamakura General Hospital, Kamakura, Japan
,
Manabu Morimoto3 Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan
,
Tatehiro Kagawa4 Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
,
Katsuaki Tanaka11 Gastroenterology Division, Hadano Red Cross Hospital, Hadano, Japan
&
Shin Maeda9 Department of Gastroenterology, Yokohama City University Hospital, Yokohama, Japan
 show all
Pages 385-396 | Published online: 01 Oct 2020

References

  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
  • Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491. doi:10.1053/j.gastro.2018.08.065
  • Galle PR, Forner A, Llovet JM; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
  • Boss DS, Glen H, Beijnen JH, et al. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer. 2012;106(10):1598–1604. doi:10.1038/bjc.2012.154
  • Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173. doi:10.1016/S0140-6736(18)30207-1
  • Hiraoka A, Kumada T, Atsukawa M, et al. Prognostic factor of Lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-multicenter analysis. Cancer Med. 2019;8(8):3719–3728. doi:10.1002/cam4.1909
  • Ueshima K, Nishida N, Hagiwara S, et al. Impact of baseline ALBI grade on the outcomes of hepatocellular carcinoma patients treated with lenvatinib: a multicenter study. Cancers (Basel). 2019;11(7):e952. doi:10.3390/cancers11070952
  • Tada T, Kumada T, Hiraoka A, et al. Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching. Hepatol Res. 2020;50(1):75–83. doi:10.1111/hepr.13427
  • Sasaki R, Fukushima M, Haraguchi M, et al. Response to lenvatinib is associated with optimal relative dose intensity in hepatocellular carcinoma: experience in clinical settings. Cancers (Basel). 2019;11(11):1769. doi:10.3390/cancers11111769
  • Ikeda M, Okusaka T, Mitsunaga S, et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2016;22(6):1385–1394. doi:10.1158/1078-0432.CCR-15-1354
  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. doi:10.1055/s-0030-1247132
  • Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306. doi:10.1016/j.jhep.2019.09.026
  • Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. doi:10.1016/S0140-6736(16)32453-9
  • Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. doi:10.1056/NEJMoa1717002
  • Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J. Journal of Hepatology. 2017;67(5):999–1008. doi:10.1016/j.jhep.2017.06.026
  • Hyun MH, Lee YS, Kim JH, et al. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: a meta-analysis of high-quality studies. Hepatology. 2018;68(3):977–993. doi:10.1002/hep.29883
  • Youssef AA, Issa HA, Omar MZ, et al. Serum human endothelial cell-specific molecule-1 (endocan) and vascular endothelial growth factor in cirrhotic HCV patients with hepatocellular carcinoma as predictors of mortality. Clin Exp Gastroenterol. 2018;11:431–438. doi:10.2147/CEG.S171339
  • Morimoto M, Numata K, Kondo M, et al. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: a propensity score analysis. Hepatol Res. 2015;45(3):279–287. doi:10.1111/hepr.12354
  • Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis. 2nd ed. New York: Springer; 2015.
  • Eso Y, Nakano S, Mishima M, et al. Dose intensity/body surface area ratio is a novel marker useful for predicting response to lenvatinib against hepatocellular carcinoma. Cancers (Basel). 2019;12(1):49. doi:10.3390/cancers12010049
  • Ogasawara S, Chiba T, Ooka Y, et al. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors. Invest New Drugs. 2015;33(3):729–739. doi:10.1007/s10637-015-0237-3
  • Di Maio M, Daniele B, Perrone F. Targeted therapies: role of sorafenib in HCC patients with compromised liver function. Nat Rev Clin Oncol. 2009;6(9):505–506. doi:10.1038/nrclinonc.2009.114

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.